Adam Keeton

Assistant Research Professor

Auburn University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Adam Keeton is an Assistant Research Professor at Auburn University - Harrison School of Pharmacy in the United States. His research primarily focuses on cancer therapeutics, particularly in the context of gastrointestinal, breast, and ovarian cancers. Recent articles authored by Dr. Keeton explore novel inhibitors and mechanisms targeting RAS signaling and phosphodiesterase pathways to enhance antitumor immunity and inhibit tumor growth.

Articles (10)

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Adam Keeton

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer

Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer

Suppression of Colon Tumorigenesis in Mutant Apc Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin

From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity

Novel thiazolidine derivatives as potent selective pro-apoptotic agents

PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity

Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.

Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS

Collaborators (7)

Jeremy Foote

Yulia Y. Maxuitenko

Heather Tinsley

Gary Piazza

Silas Leavesley

Donald Buchsbaum

Julienne Carstens

Make your next move.